WGS GeneDx Holdings Corp.
Company Analysis
Latest News
🔴 GeneDx is trading 4.69% down in after-hours trading amid broader market weakness
GeneDx is trading 4.69% down at $63.99, following a regular-session close at $67.14 on October 22, amid broader market weakness. - No clear company-specific...
🔴 GeneDx is trading 5.75% down today as U.S. markets and tech shares weaken
GeneDx is trading 5.75% down now at $64.50, with broader market pressure possibly contributing to the decline. - No clear company-specific announcement...
GeneDx Bets on Next-Generation DNA Reading to Crack Unsolved Rare Diseases — But Can a $2 Billion Company Deliver on the Promise?
Shares surged as GeneDx unveiled a technology upgrade that could reshape how doctors diagnose the hardest-to-solve genetic conditions — and investors quickly...
🟢 GeneDx is trading 9.3% up in pre-market after long-read whole genome sequencing plans
GeneDx is trading at $75.12, up 9.28%, in pre-market on October 21; its October 20 announcement of plans to add long-read whole genome sequencing is a likely...
GeneDx Plans Long-Read Sequencing to Improve Rare-Disease Diagnosis
GeneDx Holdings Corp. plans to add long-read whole genome sequencing (lrWGS) to its testing portfolio to improve rare-disease diagnosis. The technology is...
🟢 GeneDx rises 5.6% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 GeneDx is trading 10.28% down with no clear company-specific catalyst
GeneDx is trading at $63.00 (-10.28%), with no clear company-specific catalyst identified for the October 16 decline. - Coverage described the early drop as...
🔴 GeneDx is trading 4.01% down with no clear company-specific catalyst
GeneDx is trading at $67.41, down 4.01%, with no clear company-specific explanation for the October 16 decline in available reporting. - The latest company...
🟢 GeneDx rises 5.3% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 GeneDx is trading 5% up today with no clear catalyst identified
GeneDx is trading at $68.36, up 5.23%, as of 10:34 a.m. ET on October 14, with no clear newly reported company-specific catalyst identified. - GeneDx’s...
🔴 GeneDx is trading 4.02% down with no clear catalyst reported
GeneDx is trading 4.02% down at $64.62, with no clear company announcement or other catalyst specifically explaining the October 12 decline in available...
🔴 GeneDx is trading 5% down; no confirmed catalyst
GeneDx is trading 5% lower at $65.14, with the specific reason for the decline unconfirmed. - No verified GeneDx announcement on October 8 explains the...
🔴 GeneDx is trading 4.17% down today with no verified company-specific catalyst
GeneDx is trading 4.17% lower at $68.54, with no verified company-specific announcement explaining the decline. - The company published newborn...
🔴 GeneDx is trading 21.7% down in pre-market
GeneDx is trading 21.7% down at $56.00 in pre-market, with the cause of the October 7 decline unclear. - No verified company-specific announcement explaining...
🔴 GeneDx is trading 4.22% down with no clear company-specific catalyst identified
GeneDx is trading 4.22% down at $73.06, with available evidence not establishing a definite cause. - The price was reported as of 10:17 a.m. ET on October 6,...
🟢 GeneDx is trading 4.47% up today amid broader gains after softer September jobs data
GeneDx is trading 4.47% higher at $76.36, with broader-market strength a possible contributor on October 5, 2026. - The supplied market context shows the S&P...
🟢 GeneDx is trading 4.28% up today amid broader market gains
GeneDx is trading 4.28% higher at $74.00 on October 2, 2026, alongside broader market gains amid weaker-than-expected jobs data and lower rate-hike...
🔴 GeneDx is trading 4.3% down today amid scrutiny following a short-seller report
GeneDx is trading 4.3% lower at $72.52 as shares extend a multi-day slide amid scrutiny following a short-seller report. - Shares fell 11.80% on September 29;...
🔴 GeneDx is trading 10.02% down
GeneDx is trading 10.02% lower at $77.32, with no specific company announcement or credible report identified as a catalyst for the September 29, 2026...
🔴 GeneDx is trading 4.46% down
GeneDx is trading 4.46% down at $82.10 on September 29, 2026; no specific announcement or credible report has tied the intraday decline to a new catalyst. -...